Arvinas and Pfizer, co-developers of vepdegestrant – the most advanced of the new bifunctional protein degrader drug class – are jointly seeking a new partner to bring it to market. The firms are looking to out-license the selective oestrogen recepto... [2853 chars].. reed more
